Harrow, Inc. (NASDAQ:HROW) is one of the top small cap stocks with huge growth potential. On Might 13, Cantor Fitzgerald analyst Steve Seedhouse lowered his value goal on Harrow, Inc. (NASDAQ:HROW) from $91 to $88, whereas protecting his Obese ranking intact. The analyst made the transfer in response to Harrow’s downward revision to its near-term income expectations for VEVYE, the corporate’s flagship dry eye drug.
Picture from Insmed web site
Harrow shared its Q1 2026 outcomes on Might 11. The corporate’s quarterly income got here in at $44.2 million. Though the determine was decrease than the $47.8 million in Q1 2025, administration defined that the decline wasn’t too vital as a result of it was largely as a consequence of a one-time $8 million gross-to-net income adjustment. This adjustment was linked to new VEVYE industrial protection for high-deductible plan sufferers who surged past preliminary demand fashions.
The corporate detailed that VEVYE posted document new and complete prescriptions regardless of an 18% decline within the general branded dry eye market. Unit demand for IHEEZO, the corporate’s product for ocular anesthesia, rose 18% 12 months over 12 months, and 136% 12 months over 12 months for TRIESENCE.
Analyst Steve Seedhouse’s thesis dwelled extra on VEVYE as a result of that is Harrow’s flagship product. The analyst pointed to the one-time $8 million gross-to-net income adjustment and famous that it created a pricing strain that hit Q1 income however just isn’t anticipated to recur. For that purpose, he minimize income expectations for the product, and by extension, satisfied him to regulate the value goal.
Harrow, Inc. (NASDAQ:HROW) is an ophthalmic pharmaceutical firm that develops and markets medicines for eye care therapies. Its portfolio consists of merchandise for glaucoma, dry eye illness, post-surgical care, and different ophthalmic situations.
Whereas we acknowledge the potential of HROW as an funding, we imagine sure AI shares supply higher upside potential and carry much less draw back danger. In the event you’re in search of an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the best short-term AI stock.
READ NEXT: Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks and Top 10 Stocks to Buy for Long Term.
Disclosure: None. Follow Insider Monkey on Google News.
